Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

FDA Panel Backs Approval Of Biomarin Pharmaceutical Inc's Morquio A Syndrome Drug-Reuters


Tuesday, 19 Nov 2013 04:10pm EST 

Reuters reported that a federal advisory panel has recommended approval of an experimental drug to treat a rare genetic disorder known as Morquio A Syndrome that causes skeletal malformation and a variety of related lung, eye, ear and heart problems. The panel recommended that the U.S. Food and Drug Administration approve the drug, Vimizim, which is made by BioMarin Pharmaceutical Inc. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so. 

Company Quote

93.84
2.01 +2.19%
19 Dec 2014